Founded in 2009, Kintor Pharma focuses on developing innovative small molecules and biologic drugs for dermatology and oncology with substantial unmet needs, especially androgen receptor-related diseases.

On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.

Kintor Pharma's product pipeline consists of seven ongoing clinical products, including androgen receptor antagonists, AR-PROTAC, ALK-1 monoclonal antibody, Hedgehog/SMO inhibitor, mTOR inhibitor and PD-L1/TGF-β dual-targeting antiobdy. The company also has ongoing preclinical programs in ALK-1/VEGF dual-targeting antibody and c-Myc inhibitors.

Kintor Pharma has been granted more than 110 patents worldwide. Many of the company's projects were listed as National Special Projects for Significant Novel Drugs Development during the 12th (2011-2015) and 13th (2016-2020) Five-Year Plans.

In August 2020, Kintor Pharma announced that the capitalization of its Suzhou Industrial Park research and development (R&D) center and manufacturing facility. The facility covers some 20,000 square meters. Designed to meet all of Kintor Pharma's manufacturing needs, the facility was designed and constructed using state-of-the-art technologies and complies with international good manufacturing practices (GMP) standards.

Kintor Pharms's management team has extensive experience in the research and development of novel drugs and the management of start-up pharmaceutical companies. Under their leadership, the company has attracted a group of outstanding domestic and foreign professionals experienced with managing all aspects of drug development and leading multinational pharmaceutical companies.